Chronic graft versus host disease

被引:97
作者
Baird, Kristin
Pavletic, Steven Z.
机构
[1] NCI, Graft Versus Host & Autoimmun Unit, Expt Transplantat & Immunol Branch, NIH, Bethesda, MD 20892 USA
[2] NCI, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA
关键词
allogeneic hematopoietic stem cell transplant; chronic graft versus host disease; immunosuppression;
D O I
10.1097/01.moh.0000245689.47333.ff
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review Chronic graft versus host disease is a debilitating and often fatal complication of allogeneic stem cell transplantation. The purpose of this review is to overview this disease and highlight recent findings in the literature over the past year. Recent findings A new focus on chronic graft versus host disease as a long-term complication of transplantation has resulted in increased research activity in this disease. Here we review the recent in-vitro and clinical studies that focus on the pathophysiology of the disease, treatment and prevention. Summary As more patients undergo and survive allogeneic stem cell transplantation more attention is being focused on the study of chronic graft versus host disease. Although the pathophysiology is still controversial, recent advances have been made in our understanding of this disease, including the balance of T helper type 1 and 2 cells, the role of B cells and autoantibodies, graft manipulation and prophylaxis, which may lead to advances in treatment and prevention. The series of recent publications put forward by the National Institutes of Health consensus project on criteria for clinical trials are expected to advance the standards and uniformity of chronic graft versus host disease clinical research.
引用
收藏
页码:426 / 435
页数:10
相关论文
共 59 条
[1]   Development of a prognostic model for grading chronic graft-versus-host disease [J].
Akpek, G ;
Zahurak, ML ;
Piantadosi, S ;
Margolis, J ;
Doherty, J ;
Davidson, R ;
Vogelsang, GB .
BLOOD, 2001, 97 (05) :1219-1226
[2]   Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: An individual patient data meta-analysis of nine randomized trials [J].
al-Jurf, M ;
Aranha, F ;
Annassetti, C ;
Apperley, JF ;
Baynes, R ;
Bensinger, WI ;
Blaise, D ;
Chaudhary, MA ;
Clarke, M ;
Cornelissen, JJ ;
Couban, S ;
Cutler, C ;
Djulbegovic, B ;
Gyger, M ;
Gratwohl, A ;
Heldal, D ;
Van der Holt, B ;
Hozo, I ;
Kuentz, M ;
Kumar, A ;
Lipton, J ;
Matchamm, J ;
Mohty, M ;
Morton, J ;
Panzarella, T ;
Powles, R ;
Richards, SM ;
Sahovic, E ;
Schmitz, N ;
Simpson, DR ;
Sirohi, B ;
Soares, HP ;
de Souza, CA ;
Vigorito, AC ;
Wheatley, K .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :5074-5087
[3]   Late effects of chronic graft-vs.-host disease in minor salivary glands [J].
Alborghetti, MR ;
Corrêa, MEP ;
Adam, RL ;
Metze, K ;
Coracin, FL ;
de Souza, CA ;
Cintra, ML .
JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2005, 34 (08) :486-493
[4]   Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: Long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation [J].
Bacigalupo, A ;
Lamparelli, T ;
Barisione, G ;
Bruzzi, P ;
Guidi, S ;
Alessandrino, PE ;
di Bartolomeo, P ;
Oneto, R ;
Bruno, B ;
Sacchi, N ;
van Lint, MT ;
Bosi, A .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (05) :560-565
[5]   TGF-β in allogeneic stem cell transplantation:: friend or foe? [J].
Banovic, T ;
MacDonald, KPA ;
Morris, ES ;
Rowe, V ;
Kuns, R ;
Don, A ;
Kelly, J ;
Ledbetter, S ;
Clouston, AD ;
Hill, GR .
BLOOD, 2005, 106 (06) :2206-2214
[6]   High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation [J].
Baron, F ;
Maris, MB ;
Storer, BE ;
Sandmaier, BM ;
Panse, JP ;
Chauncey, TR ;
Sorror, M ;
Little, MT ;
Maloney, DG ;
Storb, R ;
Heimfeld, S .
LEUKEMIA, 2005, 19 (05) :822-828
[7]   Extending postgrafting cyclosporine decreases the risk of severe graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation [J].
Burroughs, L ;
Mielcarek, M ;
Leisenring, W ;
Sandmaier, BM ;
Maloney, DG ;
Baron, F ;
Martin, PJ ;
Flowers, MED ;
Forman, SJ ;
Chauncey, TR ;
Bruno, B ;
Storb, R .
TRANSPLANTATION, 2006, 81 (06) :818-825
[8]   Chronic graft-versus-host disease after reduced-intensity stem cell transplantation versus conventional hematopoietic stem cell transplantation [J].
Busca, A ;
Rendine, S ;
Locatelli, F ;
Sizzano, F ;
Dall'Omo, AM ;
Rossi, G ;
Falda, M .
HEMATOLOGY, 2005, 10 (01) :1-10
[9]   Can only partial T-cell depletion of the graft before hematopoietic stem cell transplantation mitigate graft-versus-host disease while preserving a graft-versus-leukemia reaction? A prospective phase II study [J].
Chalandon, Y ;
Roosnek, E ;
Mermillod, B ;
Waelchli, L ;
Helg, C ;
Chapuis, B .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (01) :102-110
[10]   Nephrotic syndrome after allogeneic hematopoietic stem cell transplantation as a late complication of chronic graft-versus-host disease [J].
Colombo, AA ;
Rusconi, C ;
Esposito, C ;
Bernasconi, P ;
Caldera, D ;
Lazzarino, M ;
Alessandrino, EP .
TRANSPLANTATION, 2006, 81 (08) :1087-1092